18-Mar-2022 - Bruker Corporation

Bruker Appoints Philip Ma to its Board of Directors

Bruker Corporation announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022.

Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief Business Officer, President, and co-founder of proteomics company Seer. Prior to this, he was Vice President for Digital Health Technologies and Data Sciences at Biogen. Before joining Biogen, Dr. Ma was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice. Dr. Ma was a macromolecular crystallographer at the Massachusetts Institute of Technology, where he earned his Ph.D. in biology. Philip also has an A.B. degree in biochemistry from Harvard University, and a M.Phil in economics from Oxford University, where he was a Rhodes Scholar.

“We are very pleased to welcome Philip to the Bruker board. Philip brings a wealth of experience in life science, multiomics technology, cancer biomarker diagnostics, and the global biopharma business, including his recent experience as co-founder of two very innovative companies. Philip also has deep insights into molecular biology, proteomics, and the latest in big data software and artificial intelligence/deep learning applications,” said Frank H. Laukien, Bruker’s Chairman, President, and CEO. “The addition of Philip to our board is timely as we continue to advance our Project Accelerate 2.0 initiatives in multiomics life science and clinical research tools. Philip shares our ‘innovation with integrity’ entrepreneurial culture, and our goals to serve life science and medical research customers with differentiated, high-value systems and solutions, to enhance value for all of Bruker’s stakeholders.”

“I am excited about joining Bruker’s board at this important time in the company’s development. The future of life sciences research increasingly focuses on probing more deeply into the interplay of proteins, nucleic acids, and metabolites in a systems biology view of key mechanisms, including that of disease. The research and diagnostic products that Bruker provides today, and which it is developing, will greatly enable this vision of research and health care. I look forward to working with Frank and the Bruker team to plan and work towards this exciting future,” commented Dr. Ma.

Facts, background information, dossiers
  • Bruker
  • appointments
More about Bruker
  • News

    Bruker Announces Acquisition of Inscopix for Neuroscience Research

    Bruker Corporation announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. Since its founding in 2011, Inscopix's flagship miniscope systems have been deployed in over 600 ... more

    Bruker and TOFWERK Form Strategic Partnership

    Bruker Corporation and TOFWERK AG announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK.  The partnership provides a basis for technology collaborations to advance instrument ... more

    Bruker Acquires Prolab Instruments

    Bruker Corporation announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems. Financial terms of the transaction were not disclosed. Mr. Werner Doebelin, the Founder and CEO of Prolab ... more

  • Products

    FT-IR and IR laser imaging (QCL) microscope for research and development

    Diffraction limited high sensitivity (FT-)IR microscopy and imaging at maximum speed ✓ Infrared laser imaging in all measurement modes (ATR, Transmission, Reflectance) ✓ Coherence reduction for artifact free Laser Imaging measurements without sensitivity or speed loss ✓ more

    FT-IR spectrometer of the future: INVENIO

    IR spectrometer for research and demanding analysis ✓ The world's most advanced interferometer & detector technology ✓ 100% designed for reliability, productivity and highest data quality ✓ more

    Spectroscopy in a New Light: FT-NIR made easy

    Maximum Flexibility: The MPA II is custom-build for you to match your very own application needs ✓ Easy Operation: Even untrained personnel can use the MPA II spectrometer from day one ✓ Green Technology: By saving energy and chemicals, the MPA II can reduce your ecological footprint ✓ more